Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma
JAMA Dermatology · 2025
DOI: 10.1001/jamadermatol.2025.0318 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Dermatology, 2025. Verfasst von Serigne N Lo und 32 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Sentinel Lymph Node. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The Melanoma Institute Australia (MIA) sentinel node (SN) metastasis risk calculator provides estimates of positivity for individual patients based on 6 standard clinicopathological parameters and the full 6-parameter model has been externally validated previously using US data. However, given its geographically widespread use, further validation is required to ensure its applicability to other populations.
Objective
To further externally validate the MIA SN metastasis risk calculator and increase its precision by refinement of the 95% CIs. Design, Setting, and Participants A retrospective multicenter cohort study was carried out using data from 4 continents, including the national Danish Melanoma Database and cancer centers in the UK (n = 3), US (n = 2), New Zealand (n = 1), Sweden (n = 1), and Brazil (n = 1). All patients aged 18 years or older who had an SN biopsy performed for an invasive primary cutaneous melanoma and data available on the following parameters: SN status, patient age at diagnosis, Breslow thickness, and melanoma subtype were included (n = 15 731). Available data were also collected on ulceration status, lymphovascular invasion, and the tumor mitotic rate. Data were collected between July 2021 and December 2023, and the analysis was conducted between January 2024 and June 2024. Main Outcomes and Measures The primary outcome was the area under the curve (AUC) of the receiver operating characteristics for the full (6-parameter) risk prediction model. Secondary outcomes were the AUCs for each country and for the limited models (3-5 parameters), the model calibration, and the recalculated 95% CIs for the models. Decision curve analysis was performed to assess the tool’s clinical utility.
Results
The whole pooled cohort consisted of 15 731 patients; 4989 had all 6 parameters available. The AUC was 73.0% (95% CI, 70.6%-75.3%) in the subset with all 6 parameters available, and 70.8%, 71.5%, and 70.1% when 1, 2, or 3 optional parameters were missing, respectively. Calibration was excellent, with an intercept and calibration slope of 0.01 (95% CI, −0.02 to 0.03) and 1.03 (95% CI, 0.90-1.16), respectively. The updated 95% CI ranges were substantially tighter, with a median reduction of more than 75%. Conclusions and Relevance This study found that the MIA SN-positivity calculator performed best with all 6 parameters and has been significantly improved (version 2), with the same risk point estimates but much tighter 95% CIs. These results demonstrated that the calculator was robust, precise, and applicable to geographically widespread melanoma populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Melanoma Institute Australia, Sydney, New South Wales, Australia.
- Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
- Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.
- Department of Plastic Surgery, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark.
- Department of Plastic & Reconstructive Surgery, Norfolk & Norwich University Hospital Foundation NHS Trust, Norwich, United Kingdom.
- Department of Plastic Surgery, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Zitieren
APA
Lo, S. N., Gjorup, C., Chakera, A. H., Hölmich, L. R., Moncrieff, M., MacKenzie Ross, A., Cassell, O., Ma, J., Weitemeyer, M. B., Olofsson Bagge, R., Klausen, S., Calsavara, V. F., Duprat Neto, J. P., Bertolli, E., Ch'ng, S., Saw, R. P. M., Shannon, K. F., Spillane, A. J., Nieweg, O. E., …, & Varey, A. H. R. (2025). Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2025.0318
Vancouver
Lo SN, Gjorup C, Chakera AH, Hölmich LR, Moncrieff M, MacKenzie Ross A, et al. Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma. JAMA Dermatology. 2025. doi:10.1001/jamadermatol.2025.0318
BibTeX
@article{Lo2025,
author = {Lo, Serigne N and Gjorup, Caroline and Chakera, Annette Hougaard and Hölmich, Lisbet Rosenkrantz and Moncrieff, Marc and MacKenzie Ross, Alastair and Cassell, Oliver and Ma, Jiawen and Weitemeyer, Marie Brinch-Møller and Olofsson Bagge, Roger and Klausen, Siri and Calsavara, Vinicius F and Duprat Neto, João P and Bertolli, Eduardo and Ch'ng, Sydney and Saw, Robyn P M and Shannon, Kerwin F and Spillane, Andrew J and Nieweg, Omgo E and Stretch, Jonathan R and Mann, Graham J and Geh, Jenny L C and Haydu, Lauren E and Martin, Richard C W and Sharon, Cimarron and Karakousis, Giorgos C and Kashani-Sabet, Mohammed and Adigbli, George and El Sharouni, Mary-Ann and Gershenwald, Jeffrey E and Scolyer, Richard A and Thompson, John F and Varey, Alexander H R},
title = {Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma},
journal = {JAMA Dermatology},
year = {2025},
doi = {10.1001/jamadermatol.2025.0318}
}
EUVIMED